Stock NOVARTIND NOVARTIS INDIA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Novartis India Limited

Equities

NOVARTIND

INE234A01025

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:10:45 2024-04-26 am EDT 		5-day change 1st Jan Change
1,055 INR +0.88% Intraday chart for Novartis India Limited +4.37% +36.45%
Apr. 01 Novartis India Limited Announces Resignation of Nikhil Malpani as Company Secretary and Compliance Officer, Effective from April 30, 2024 CI
Mar. 22 Novartis Eyes Sale of Listed Unit in India CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 15,118 16,933 12,401 13,629 14,579 13,958
Enterprise Value (EV) 1 7,383 10,828 7,280 9,280 9,656 8,629
P/E ratio 21.5 x 32.7 x 123 x 65.2 x -392 x 13.5 x
Yield 1.63% 1.46% 1.99% 1.81% 1.69% 1.77%
Capitalization / Revenue 2.68 x 3.45 x 2.83 x 3.57 x 3.65 x 3.69 x
EV / Revenue 1.31 x 2.21 x 1.66 x 2.43 x 2.41 x 2.28 x
EV / EBITDA -125 x 68.4 x 154 x 51.9 x 37.6 x 14 x
EV / FCF 6.02 x -6.5 x 63.1 x -18.4 x 7.95 x 15.2 x
FCF Yield 16.6% -15.4% 1.58% -5.44% 12.6% 6.58%
Price to Book 2.06 x 2.23 x 1.72 x 1.92 x 2.11 x 1.8 x
Nbr of stocks (in thousands) 24,691 24,691 24,691 24,691 24,691 24,691
Reference price 2 612.3 685.8 502.2 552.0 590.4 565.3
Announcement Date 8/2/18 7/8/19 7/10/20 7/30/21 6/30/22 6/30/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 5,639 4,907 4,382 3,814 3,999 3,787
EBITDA 1 -59 158.3 47.3 178.9 256.5 618.4
EBIT 1 -84.3 126.5 8.4 147.7 237.7 600.8
Operating Margin -1.49% 2.58% 0.19% 3.87% 5.94% 15.86%
Earnings before Tax (EBT) 1 1,575 857.7 286.4 400.4 -38.2 1,154
Net income 1 783.6 517.7 100.8 209 -37.2 1,034
Net margin 13.9% 10.55% 2.3% 5.48% -0.93% 27.29%
EPS 2 28.43 20.97 4.082 8.465 -1.507 41.86
Free Cash Flow 1 1,226 -1,667 115.3 -504.7 1,215 568.2
FCF margin 21.74% -33.97% 2.63% -13.23% 30.37% 15%
FCF Conversion (EBITDA) - - 243.79% - 473.52% 91.88%
FCF Conversion (Net income) 156.46% - 114.4% - - 54.97%
Dividend per Share 2 10.00 10.00 10.00 10.00 10.00 10.00
Announcement Date 8/2/18 7/8/19 7/10/20 7/30/21 6/30/22 6/30/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 7,735 6,105 5,121 4,349 4,923 5,329
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 1,226 -1,667 115 -505 1,215 568
ROE (net income / shareholders' equity) 9.48% 6.94% 1.36% 2.92% -0.53% 14.1%
ROA (Net income/ Total Assets) -0.47% 0.76% 0.05% 0.89% 1.52% 3.87%
Assets 1 -168,118 68,524 198,035 23,547 -2,454 26,707
Book Value Per Share 2 297.0 307.0 292.0 288.0 280.0 314.0
Cash Flow per Share 2 15.20 35.50 32.00 27.60 64.10 7.870
Capex 1 8 141 10 0.9 5 3.1
Capex / Sales 0.14% 2.87% 0.23% 0.02% 0.13% 0.08%
Announcement Date 8/2/18 7/8/19 7/10/20 7/30/21 6/30/22 6/30/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
NOVARTIS INDIA LIMITED Stock Novartis India Limited
+36.45% 312M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. NOVARTIND Stock
  4. Financials Novartis India Limited